UNITY Biotechnology

The new age of senolytics – restoring aging, diseased tissue to a healthier state

Pioneers in novel aging mechanisms: Through their senolytic platform, UNITY is developing a novel therapeutic approach to remodel the retina. They are the first company to produce Phase 2 proof-of-concept data that validates their senolytic approach by targeting destructive senescent cells in retinal tissues, while preserving healthy cells, a potentially paradigm shifting approach to treating vision loss in diabetic macular edema (DME).

Sights set on age-related vision loss: Lead senolytic candidate UBX1325 has produced impressive data as an entirely novel mechanism of action showing that one injection not only stabilized retinal structure but improved vision for almost one year in a very difficult-to-treat DME patient population – a clear benefit over current medicines that require frequent injections for diminishing benefits. Now, the company is conducting a Phase 2b study to discern how their senolytic therapeutic approach compares head-to-head with current standards of care.
Key Events in 2025:Initial head-to-head Phase 2b ASPIRE data in DME anticipated in Q1 2025; and 36-week data expected in 2Q 2025.